RARECELLSDETECT AND DEFEAT CANCER FROM ITS START THROUGH A SIMPLE BLOOD DRAWMOREISET® PLATFORMVERSATILITY, SENSITIVITY INTACT LABEL-FREE FIXED AND LIVING CELLS FROM A BLOOD DRAWMOREAPPLICATIONSFOSTER YOUR RESEARCH STUDIES ACCESSING THE RIGHT CIRCULATING TUMOR CELLS & CTC DNAMORE RARECELLSOUTSMARTING CANCER FROM ONSET TO REMISSIONMOREISET® PLATFORMVERSATILITY, SENSITIVITY INTACT LABEL-FREE FIXED AND LIVING CELLS FROM A BLOOD DRAWMOREAPPLICATIONSFOSTER YOUR RESEARCH STUDIES ACCESSING THE RIGHT CIRCULATING TUMOR CELLS & CTC DNAMORE RARECELLSDETECT AND DEFEAT CANCER FROM ITS START THROUGH A SIMPLE BLOOD DRAWMOREISET® PLATFORMVERSATILITY, SENSITIVITY INTACT LABEL-FREE FIXED AND LIVING CELLS FROM A BLOOD DRAWMOREAPPLICATIONSBOOST YOUR RESEARCH STUDIES ACCESSING THE RIGHT CIRCULATING TUMOR CELLS & CTC DNAMORE RARECELLS FROM RESEARCH TO CLINIC From a 10mL blood draw, ISET® system is capturing intact CTC ready for downstream analysis from cytology to DNA analysis. ISET® isolated CTC, a reliable source to foster research applied to early detection, prognosis, and theranostic Learn more about the ISET® cytology blood test ANY QUESTIONS? NEED FOR INFORMATION? CONTACT US LEARN ABOUT ISET TECHNOLOGY AND CTC NEWS Rarecells Announces New Clinical Data Showing Superior Sensitivity and Tumor Heterogeneity Detection by Synergistic Combination of ctDNA and ISET® CTC-DNA in Patients with Early-Stage Lung Cancer READ MORE » September 9, 2025 Vanity Fair Italy Interviews Rarecells Founder Dr. Patrizia Paterlini READ MORE » June 30, 2025 Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board READ MORE » June 18, 2025
Rarecells Announces New Clinical Data Showing Superior Sensitivity and Tumor Heterogeneity Detection by Synergistic Combination of ctDNA and ISET® CTC-DNA in Patients with Early-Stage Lung Cancer READ MORE » September 9, 2025